NCI-MATCH Results Offer Clues for the Use of Agents Across Tumor Types

Jason Harris
Published: Friday, Feb 01, 2019
Lyndsay Harris, MD

Lyndsay Harris, MD

A trickle of positive findings from NCI-MATCH, a precision medicine trial of numerous agents across tumor types, has encouraged investigators to broaden the number of trial arms, which now stand at 40, and expand enrollment. Since the trial’s inception in 2015, molecular testing has been conducted on the tumors of 6000 patients and many arms have already closed to enrollment. Investigators expect to report more findings soon.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x